Search Videos by Topic or Participant
Browse by Series:

Final Thoughts on AML and ALL

Panelists: Dan Douer, MD, MSK; Richard M. Harris, MD, Cedars Sinai; Jeffrey Lancet, MD, Moffitt; Mark R. Litzow, MD, Mayo Clinic; Leonard S. Sender
Published: Thursday, May 14, 2015
For High-Definition, Click
Acute myeloid leukemia (AML) is a relatively uncommon disease, Jeffrey Lancet, MD, states. Given its rarity, more individuals with AML should enroll in clinical trials in order to advance care.
 
The increasing use of minimal residual disease assessment to identify individuals with high-risk B-cell acute lymphoblastic leukemia (ALL) may provide benefit for patients in a disease that has been stalled in the adult setting for so many years, comments Mark R. Litzow, MD.
 
Dan Douer, MD, adds that novel treatment modalities that harness the patient’s own immune system rather than a donor’s immune system lie in the future of ALL management.
 
Raoul Tibes, MD, recommends that future practice include intensified pediatric regimens in young adults and incorporate new targeted therapies, such as blinatumomab, to achieve longer remissions.
Slider Left
Slider Right
For High-Definition, Click
Acute myeloid leukemia (AML) is a relatively uncommon disease, Jeffrey Lancet, MD, states. Given its rarity, more individuals with AML should enroll in clinical trials in order to advance care.
 
The increasing use of minimal residual disease assessment to identify individuals with high-risk B-cell acute lymphoblastic leukemia (ALL) may provide benefit for patients in a disease that has been stalled in the adult setting for so many years, comments Mark R. Litzow, MD.
 
Dan Douer, MD, adds that novel treatment modalities that harness the patient’s own immune system rather than a donor’s immune system lie in the future of ALL management.
 
Raoul Tibes, MD, recommends that future practice include intensified pediatric regimens in young adults and incorporate new targeted therapies, such as blinatumomab, to achieve longer remissions.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x